AU4977896A - Immunotherapy screening, prognosis, and treatment methods and compositions - Google Patents
Immunotherapy screening, prognosis, and treatment methods and compositionsInfo
- Publication number
- AU4977896A AU4977896A AU49778/96A AU4977896A AU4977896A AU 4977896 A AU4977896 A AU 4977896A AU 49778/96 A AU49778/96 A AU 49778/96A AU 4977896 A AU4977896 A AU 4977896A AU 4977896 A AU4977896 A AU 4977896A
- Authority
- AU
- Australia
- Prior art keywords
- prognosis
- compositions
- treatment methods
- immunotherapy
- screening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000004393 prognosis Methods 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39255395A | 1995-02-17 | 1995-02-17 | |
US48185795A | 1995-06-07 | 1995-06-07 | |
US481857 | 1995-06-07 | ||
PCT/US1996/001876 WO1996025664A1 (en) | 1995-02-17 | 1996-02-12 | Immunotherapy screening, prognosis, and treatment methods and compositions |
US392553 | 2003-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4977896A true AU4977896A (en) | 1996-09-04 |
Family
ID=27013925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU49778/96A Abandoned AU4977896A (en) | 1995-02-17 | 1996-02-12 | Immunotherapy screening, prognosis, and treatment methods and compositions |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4977896A (en) |
IL (1) | IL117159A0 (en) |
WO (1) | WO1996025664A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1991097A (en) * | 1996-03-15 | 1997-10-01 | Immunotherapy, Inc. | Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases |
GB9706957D0 (en) | 1997-04-05 | 1997-05-21 | Smithkline Beecham Plc | Formulation |
WO2000011476A1 (en) * | 1998-08-25 | 2000-03-02 | The Immune Response Corporation | Methods for evaluating immune function |
GB9820525D0 (en) | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
GB0000891D0 (en) | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
US20070154399A1 (en) * | 2000-10-27 | 2007-07-05 | Hadden John W | Immunotherapy for immune suppressed patients |
EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
EP2073011A1 (en) * | 2007-12-20 | 2009-06-24 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods of processing biological samples |
AU2022422062A1 (en) * | 2021-12-22 | 2024-07-18 | Cj Cheiljedang Corporation | Antiviral composition comprising nucleoside analogues derived from nucleic acid and pharmaceutically acceptable salt thereof |
KR102584927B1 (en) * | 2021-12-22 | 2023-10-06 | 씨제이제일제당 (주) | Antiviral composition comprising nucleoside analogues derived from nucleic acid or pharmaceutically acceptable salt thereof |
WO2024144320A1 (en) * | 2022-12-29 | 2024-07-04 | 씨제이제일제당 (주) | Antiviral composition comprising nucleoside analogues derived from nucleic acid and pharmaceutically acceptable salts thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4931275A (en) * | 1985-12-02 | 1990-06-05 | Yeda Research & Development Co., Ltd. | Anti-tumor vaccines and their preparation |
EP0615758B1 (en) * | 1988-05-24 | 1999-09-22 | Yeda Research And Development Co. Ltd. | Anti-tumor vaccines |
IT1264516B1 (en) * | 1993-05-31 | 1996-09-24 | Biotop Sas Di Rita Cassarin | IMMORTALIZED DENDRITIC CELLS |
US5583713A (en) * | 1994-07-22 | 1996-12-10 | Analog Devices, Inc. | Pipelined demodulation and ADC conversion scheme for disk drive servo system |
-
1996
- 1996-02-12 WO PCT/US1996/001876 patent/WO1996025664A1/en active Application Filing
- 1996-02-12 AU AU49778/96A patent/AU4977896A/en not_active Abandoned
- 1996-02-16 IL IL11715996A patent/IL117159A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL117159A0 (en) | 1996-06-18 |
WO1996025664A1 (en) | 1996-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU694837B2 (en) | Naphthyl compounds, intermediates, compositions, and methods | |
AU6267896A (en) | Antibody and antibody fragments for inhibiting the growth oftumors | |
AU2582897A (en) | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation | |
AU5312198A (en) | Screening method | |
AU2440997A (en) | Calixpyrroles, calixpyridinopyrroles and calixpyridines | |
AU4052897A (en) | Cancer treatment method | |
AU8693098A (en) | Compositions and methods for treating diabetes | |
AU3157197A (en) | Pulley | |
AU2936897A (en) | Subchirp processing method | |
AU4977896A (en) | Immunotherapy screening, prognosis, and treatment methods and compositions | |
AU5757998A (en) | Revolving door | |
AU1320797A (en) | Ginseng processing method and processed ginseng prepared by the same | |
AU6826194A (en) | 16-hydroxytriptolide composition and method for immunotherapy | |
AU5798996A (en) | Adnaz, compositions and processes | |
AU1538497A (en) | Anti-gp46 antibodies and fragments thereof and their use | |
AU2690897A (en) | Revolving door | |
AU3200197A (en) | New composition and methods | |
EP0791407A3 (en) | Sifter | |
AU2531397A (en) | Enantiomeric screening process, and compositions therefor | |
AUPO380996A0 (en) | Scallop processing | |
AU3219897A (en) | Anti-paramyxovirus screening method and vaccine | |
AU6601096A (en) | Dax-1 protein, methods for production and use thereof | |
AU5594794A (en) | Immunotherapy composition and method | |
AU4122897A (en) | Multi-resistant bacteria, methods for obtaining them and their uses | |
AU2550497A (en) | Simplified bimodal process |